Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF (589720) quoted at RMB 0.89, with assets under management growing RMB 118 million over the past 1 week

NewTimeSpace (newtimespace.com) News, as of 10:57 on September 2, 2026, the SSE Science And Technology Innovation Board Innovative Drugs Index (950161) rose 0.40%, and the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF (589720) was quoted at RMB 0.89.

In terms of liquidity, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF recorded an intraday turnover rate of 9.36%, with turnover of RMB 418 million. Over a longer horizon, as of September 1, the ETF's average daily turnover over the past 1 month reached RMB 974 million.

In terms of scale, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's assets under management grew by RMB 118 million over the past 1 week, representing significant growth. (Source: Wind)

In terms of shares, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's latest shares outstanding reached 5.014 billion shares, hitting a new high over the past 1 year. (Source: Wind)

In terms of net fund inflows, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF recorded consecutive net inflows over the past 5 days, with a single-day peak net inflow of RMB 134 million, aggregating to RMB 293 million of net inflows ("fund attraction"), and an average daily net inflow of RMB 58.5786 million. (Source: Wind)

Data shows that leveraged funds continue to build positions. The Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's prior-trading-day net margin purchase reached RMB 6.9855 million, and its latest margin financing balance reached RMB 410 million. (Source: Wind)

As of September 1, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's NAV rose 3.87% over the past 6 months, ranking 965th out of 4,901 among index equity funds, placing it in the top 19.69%. In terms of return capability, as of September 1, 2026, since its inception, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF posted a maximum single-month return of 5.48%, a longest winning streak of 2 months, a longest rally gain of 6.23%, and an average return rate in rising months of 3.73%. As of September 1, 2026, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's annualized excess return over the benchmark over the past 3 months was 2.59%.

In terms of drawdown, as of September 1, 2026, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's drawdown relative to the benchmark over the past 6 months was 0.15%, the smallest drawdown among comparable funds. The drawdown recovery period was 25 days.

In terms of fees, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF has a management fee rate of 0.50% and a custody fee rate of 0.10%.

In terms of tracking precision, as of September 1, 2026, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's tracking error year-to-date was 0.032%.

From a valuation perspective, the SSE Science And Technology Innovation Board Innovative Drugs Index tracked by the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF (589720) has a latest price-to-earnings ratio (PE-TTM) of only 80.59x, at the 2.99% percentile over the past 1 year, meaning its valuation is below that of over 97.01% of the time over the past 1 year, sitting at a historical low.

The Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF (589720) closely tracks the SSE Science And Technology Innovation Board Innovative Drugs Index. The SSE Science And Technology Innovation Board Innovative Drugs Index selects securities of no more than 30 listed companies in the innovative drugs field from the STAR Market as index constituents, to reflect the overall performance of securities of listed companies in the innovative drugs field within the STAR Market.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.